Patients with autoimmune disease receiving ICI exhibit better survival vs. controls

Although they exhibit a greater risk for severe immune-related adverse effects, patients with preexisting autoimmune disease receiving immune checkpoint inhibitors for melanoma had better 2-year survival than controls, according to data.“Immune checkpoint inhibitors (ICIs) are one of the major therapeutic advances in oncology in the past 10 years,” Léo Plaçais, MD, of the internal medicine and clinical immunology department at Hopital Bicêtre, in France, and co-authors wrote in the Annals of the Rheumatic Diseases. “Since their first approval in metastatic melanoma andRead More